Effect of statin treatment on short term mortality after pneumonia episode: Cohort study

BMJ

Volumn 342, Issue 7801, 2011, Pages

  Douglas, Ian ^a   Evans, Stephen ^a   Smeeth, Liam ^a  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; AGED; ARTICLE; CLINICAL PRACTICE; COHORT ANALYSIS; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; MORTALITY; PNEUMONIA; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; UNITED KINGDOM; FEMALE; KAPLAN MEIER METHOD; MIDDLE AGED; RISK FACTOR;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PNEUMONIA; RISK FACTORS;

EID: 79953905093     PISSN: None     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.d1642     Document Type: Article

References (22)

1. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360:7-22.
2. Nissen SE, Tuzcu EM, Schoenhagen P, Crowe T, Sasiela WJ, Tsai J, et al. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N Engl J Med 2005;352:29-38. (Pubitemid 40075678)
3. Liao JK. Effects of statins on 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibition beyond low-density lipoprotein cholesterol. Am J Cardiol 2005;96:24-33F. (Pubitemid 41207730)
4. Smeeth L, Douglas I, Hall AJ, Hubbard R, Evans S. Effect of statins on a wide range of health outcomes: a cohort study validated by comparison with randomized trials. Br J Clin Pharmacol 2009;67:99-109.
5. Lodi S, Evans SJW, Egger P, Carpenter J. Is there an anti-inflammatory effect of statins in rheumatoid arthritis? Analysis of a large routinely collected claims database. Br J Clin Pharmacol 2009;69:85-94.
6. Tleyjeh IM, Kashour T, Hakim FA, Zimmerman VA, Erwin PJ, Sutton AJ, et al. Statins for the prevention and treatment of infections: a systematic review and meta-analysis. Arch Intern Med 2009;169:1658-67.
7. Bourke A, Dattani H, Robinson M. Feasibility study and methodology to create a quality-evaluated database of primary care data. Inform Prim Care 2004;12:171-7. (Pubitemid 39534583)
8. Lewis JD, Schinnar R, Bilker WB, Wang X, Strom BL. Validation studies of the health improvement network (THIN) database for pharmacoepidemiology research. Pharmacoepidemiol Drug Saf 2007;16:1195-2002.
9. Sturmer T, Joshi M, Glynn RJ, Avom J, Rothman KJ, Schneewelss S. A review of the application of propensity score methods yielded increasing use, advantages in specific settings, but not substantially different estimates compared with conventional multivariable methods. J Clin Epidemiol 2006;59:437-47.
10. Sturmer, Rothman KJ, Avorn J, Glynn RJ. Treatment effects in the presence of unmeasured confounding: dealing with observations in the tails of the propensity score distribution - asimulation study. Am J Epidemiol 2010;172:843-54.
11. Office for National Statistics. Guidance for doctors completing medical certificates of cause of death in England and Wales: from the Office for National Statistics' Death Certification Advisory Group. ONS, 2008.
12. Almog Y, Shefer A, Novack V, Maimon N, Barski L, Eizinger M, et al. Prior statin therapy is associated with a decreased rate of severe sepsis. Circulation 2004;110:880-5. (Pubitemid 39096018)
13. Frost FJ, Petersen H, Tollestrup K, Skipper B. Influenza and COPD mortality protection as pleiotropic, dose-dependent effects of statins. Chest 2007;131:1006-12. (Pubitemid 46608700)
14. Mortensen EM, Restrepo MI, Anzueto A, Pugh J. The effect of prior statin use on 30-day mortality for patients hospitalized with community-acquired pneumonia. Respir Res 2005;6:82.
15. Myles PR, Hubbard RB, Gibson JE, Pogson Z, Smith CJ, McKeeverTM. The impact of statins, ACE inhibitors and gastric acid suppressants on pneumonia mortality in a UK general practice population cohort. Pharmacoepidemiol Drug Saf 2009;18:697-703.
16. Majumdar SR, McAlister FA, Eurich DT, Padwal RS, Manie TJ. Statins and outcomes in patients admitted to hospital with community acquired pneumonia: population based prospective cohort study. BMJ 2006;333:999.
17. Laufs U, Wassmann S, Hilgers S, Ribaudo N, Bohm M, Nickenig G. Rapid effects on vascular function afterinitiation and withdrawal of atorvastatin in healthy, normocholesterolemic men. Am J Cardiol 2001;88:1306-7. (Pubitemid 33132103)
18. Li JJ, Fang CH, Qian HY, Hu WL. Time course of rapid C-reactive protein reduction by pravastatin in patients with stable angina. Angiology 2006;57:1-7.
19. Kwak B, Mulhaupt F, Myit S, Mach F. Statins as a newly recognised type of immunomodulator. Nat Med 2000:6;1399-402. (Pubitemid 32001026)
20. Armitage J. The safety of statins in clinical practice. Lancet 2007;370:1781-90. (Pubitemid 350137473)
21. Hackam DG, Mamdani, M, LiP, Redelmeir DA.Statins and sepsis in patients with cardiovascular disease: a population based cohort study. Lancet 2006;367:413-8. (Pubitemid 43184262)
22. Terblanche M, Almog Y, Rosenson RS, Smith TS, Hackam DG. Statins: panacea for sepsis? Lancet Infect Dis 2006;6:242-8.